Department of Health and Human Services July 8, 2021 – Federal Register Recent Federal Regulation Documents

Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2022 and Pharmacy Benefit Manager Standards; Correction
Document Number: 2021-14545
Type: Rule
Date: 2021-07-08
Agency: Department of Health and Human Services
This document corrects technical errors in the final rule that appeared in the May 5, 2021, Federal Register entitled, ``Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2022 and Pharmacy Benefit Manager Standards''.
Center for Scientific Review; Notice of Closed Meeting
Document Number: 2021-14531
Type: Notice
Date: 2021-07-08
Agency: Department of Health and Human Services, National Institutes of Health
Meeting of the Presidential Advisory Council on HIV/AIDS
Document Number: 2021-14496
Type: Notice
Date: 2021-07-08
Agency: Department of Health and Human Services
As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Service is hereby giving notice that the Presidential Advisory Council on HIV/AIDS (PACHA or the Council) will be holding the 71st full Council meeting utilizing virtual technology on Tuesday, August 3-Wednesday, August 4, 2021 from 1:00-5:00 p.m. (ET) on both days. The meeting will be open to the public; a public comment session will be held during the meeting. Pre-registration is required to provide public comment during the meeting. To pre-register to attend or to provide public comment, please send an email to PACHA@hhs.gov and include your name, organization, and title by close of business Monday, July 26, 2021. If you decide you would like to provide public comment but do not pre-register, you may submit your written statement by emailing PACHA@hhs.gov by close of business Wednesday, August 11, 2021. The meeting agenda will be posted on the PACHA page on HIV.gov at https://www.hiv.gov/federal-response/pacha/about-pacha prior to the meeting.
Determination of Regulatory Review Period for Purposes of Patent Extension; PIQRAY
Document Number: 2021-14490
Type: Notice
Date: 2021-07-08
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PIQRAY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.